Karyopharm Therapeutics Inc [KPTI] stock prices are up 15.04% to $1.53 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The KPTI shares have gain 31.90% over the last week, with a monthly amount drifted -7.83%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 6, March 2024, Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences. In a post published today on Yahoo Finance, Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company’s senior management team will participate in the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 and present at the Barclays 26th Annual Global Healthcare Conference in a fireside chat on Wednesday, March 13, 2024 at 9:00 a.m. ET in Miami Beach, FL.
From an analyst’s perspective:
Karyopharm Therapeutics Inc [NASDAQ: KPTI] stock has seen the most recent analyst activity on January 19, 2023, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $8. Previously, RBC Capital Mkts upgraded its rating to Outperform on November 04, 2022, and elevated its price target to $10. On February 09, 2022, upgrade upgraded it’s rating to Neutral but maintained its price target of $8 on the stock. SVB Leerink downgraded its rating to a Mkt Perform but $6 remained the price target by the analyst firm on August 06, 2021. RBC Capital Mkts downgraded its rating to Sector Perform for this stock on August 06, 2021, and downed its price target to $8. In a note dated August 06, 2021, JP Morgan downgraded an Neutral rating on this stock.
The stock price of Karyopharm Therapeutics Inc [KPTI] has been fluctuating between $0.62 and $4.87 over the past year. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. Karyopharm Therapeutics Inc [NASDAQ: KPTI] shares were valued at $1.53 at the most recent close of the market. An investor can expect a potential return of 488.24% based on the average KPTI price forecast.
Analyzing the KPTI fundamentals
The Karyopharm Therapeutics Inc [NASDAQ:KPTI] reported sales of 146.03M for trailing twelve months, representing a surge of 0.50%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -0.89%, Pretax Profit Margin comes in at -0.98%, and Net Profit Margin reading is -0.98%. To continue investigating profitability, this company’s Return on Assets is posted at -0.6, Equity is 1.62 and Total Capital is -0.76. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3567 points at the first support level, and at 1.1833 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6567, and for the 2nd resistance point, it is at 1.7833.
Ratios To Look Out For
It’s worth pointing out that Karyopharm Therapeutics Inc [NASDAQ:KPTI]’s Current Ratio is 3.37. In addition, the Quick Ratio stands at 3.32 and the Cash Ratio stands at 0.76. Considering the valuation of this stock, the price to sales ratio is 1.21.
Transactions by insiders
Recent insider trading involved Paulson Richard A., President and CEO, that happened on Mar 05 ’24 when 3573.0 shares were sold. President and CEO, Paulson Richard A. completed a deal on Mar 01 ’24 to sell 19374.0 shares. Meanwhile, EVP, CFO & Treasurer Mason Michael sold 6162.0 shares on Mar 01 ’24.
